Search

Subject Electronic journals

15211. 209 The sum of gains and losses of genes encoding for protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment. (September 2015)

Authors:
Jiang, X.; Pissaloux, D.; De La Fouchardiere, C.; Desseigne, F.; Wang, Q.; Fondrevelle, M.E.; Cassier, P.; Seigne, C.; Perol, D.; Ray-Coquard, I.; Le Cesne, A.; Penel, N.; Tredan, O.; Blay, J.Y.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S30
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15214. 2090 Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC). (September 2015)

Authors:
Kramar, A.; Paule, B.; Burtin, P; Tougeron, D.; Desseigne, F.; Dourthe, L.M.; Wallet, J.; Etienne, PL.; Mineur, L.; Becuwe, C.; Maes, P; Dauba, J.; Michel, P; Hollebecque, A.; Linot, B.; Morere, J.F.; Fouchardiere, C. De la; Phelip, J.M.; Andre, T.; Adenis, A.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S358
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15216. 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. (September 2015)

Authors:
Nakatsumi, H.; Yuki, S.; Kawamoto, Y.; Muranaka, T.; Hatanaka, K.; Kato, T.; Meguro, T.; Nakamura, M.; Iwanaga, I.; Uebayashi, M.; Tateyama, M.; Eto, K.; Kudo, M.; Kato, S.; Okuda, H.; Sogabe, S.; Miyashita, K.; Sakata, Y.; Sakamoto, N.; Komatsu, Y.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S358
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15218. 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. (September 2015)

Authors:
Kobayashi, Y.; Yuki, S.; Kawamoto, Y.; Sawada, K.; Miyagishima, T.; Ehira, N.; Iwanaga, I.; Okuda, H.; Tateyama, M.; Tsuji, Y.; Hatanaka, K.; Nakamura, M.; Kudo, M.; Fukushima, H.; Tagaki, T.; Hisai, H.; Koike, M.; Abe, R.; Sakata, Y.; Komatsu, Y.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S359
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15219. 2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. (September 2015)

Authors:
Fontaniere, C. De La Fouchardiere; Paule, B.; Burtin, P; Wallet, J.; Tougeron, D.; Dourthe, L.M.; Etienne, P.L.; Mineur, L.; Becuwe, C.; Maes, P.; Dauba, J.; Michel, P.; Wendling, J.L.; Linot, B.; Hollebecque, A.; Clisant, S.; Morere, J.F.; Andre, T.; Phelip, J.M.; Adenis, A.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S360
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15220. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. (September 2015)

Authors:
Nakamura, M.; Yuki, S.; Nakatsumi, H.; Muto, O.; Hosokawa, A.; Kato, T.; Iwanaga, I.; Hatanaka, K.; Tsuji, Y.; Sato, A.; Eto, K.; Furukawa, K.; Okuda, H.; Onodera, M.; Fujikawa, K.; Kudo, M.; Yokoyama, S.; Honda, T.; Sakata, Y.; Komatsu, Y.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S360
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗